OptiNose(US:OPTN)2020-11-06 16:45Q3 2020 Performance Highlights - XHANCE net revenue increased by 78% compared to Q3 2019[5, 24] - XHANCE TRx (total prescriptions) grew by 61% in Q3 2020 compared to Q3 2019[5, 12] - XHANCE net revenue per TRx was $224 in Q3 2020, an increase from $164 in Q2 2020[5, 24] - XHANCE achieved a 5.7% market share within the target physician audience in Q3 2020, a 2.7% increase compared to Q3 2019's 3.0% share[5, 16] - New prescriptions of XHANCE increased 23% in Q3 2020 compared to Q2 2020 and increased 29% in Q3 2020 compared to Q3 2019[9] Financial Position and Guidance - Cash and equivalents were $143 million as of September 30, 2020[6, 30, 32] - Full year 2020 operating expense guidance is lowered to between $127 million and $132 million, including approximately $10 million in stock-based compensation[5, 26] - The company qualified to draw $20 million from a debt facility due to Q3 2020 XHANCE net revenues exceeding $14.5 million and expects to draw it by early 2021[5, 26] Strategic Initiatives - Successful launch of kaléo co-promotion on October 1st[5, 30] - Physicians who had more than 15 XHANCE prescriptions filled by their patients in a quarter increased by 73% from Q3 2019 to Q3 2020 (1,153 versus 665)[19]